BUDGET IMPACT ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) IN BRAZIL

被引：0
|
作者：
Asano, E. [1 ]
Nita, M. [1 ]
Moellmann-Coelho, A. [2 ]
Rached, R. [1 ]
Donato, B. [3 ]
Rahal, E. [1 ]
机构：
[1] Bristol Myers Squibb SA, Sao Paulo, Brazil
[2] Inst Nacl Canc INCA, Rio De Janeiro, Brazil
[3] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74285-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A262 / A262
页数：1
相关论文
共 50 条
  • [1] BUDGET IMPACT ANALYSIS OF DASATINIB IN IMATINIB-RESISTANT OR-INTOLERANT PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) IN THE CHINESE SETTING
    Wu, B.
    VALUE IN HEALTH, 2016, 19 (07) : A881 - A881
  • [2] COST-EFFECTIVENESS ANALYSIS OF NILOTINIB VERSUS DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT OR IMATINIB-INTOLERANT CHRONIC MYELOID LEUKEMIA (CML)
    Niu, X.
    Hay, J.
    VALUE IN HEALTH, 2012, 15 (04) : A209 - A210
  • [3] COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) ON CHRONIC (CP), ACCELERATED (AP) AND BLAST (BP) PHASES IN BRAZIL
    Asano, E.
    Nita, M.
    Moellmann-Coelho, A.
    Rached, R.
    Donato, B.
    Rahal, E.
    VALUE IN HEALTH, 2009, 12 (07) : A280 - A281
  • [4] DASATINIB TREATMENT OF IMATINIB-RESISTANT AND IMATINIB-INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN A CHRONIC PHASE
    Vinogradova, O. Yu.
    Turkina, A. G.
    Vorontsova, A. V.
    Chelysheva, E. Yu.
    Gusarova, G. A.
    Kuznetsov, S. V.
    Goryacheva, S. R.
    Sokolova, M. A.
    Abakumov, E. M.
    Stakhina, O. V.
    Domracheva, E. V.
    Misyurin, A. V.
    Khoroshko, N. D.
    TERAPEVTICHESKII ARKHIV, 2009, 81 (07) : 41 - 46
  • [5] Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
    Chuah, Charles
    Melo, Junia V.
    ONCOTARGETS AND THERAPY, 2009, 2 : 83 - 94
  • [6] Dasatinib is effective in imatinib-resistant CML
    Cannell, Emma
    LANCET ONCOLOGY, 2007, 8 (04): : 286 - 286
  • [7] Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML)
    Giles, Francis J.
    Yin, Ophelia
    Chia, Yen Lin
    le Coutre, Philipp D.
    Woodman, Richard C.
    Ottmann, Oliver G.
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 390 - 390
  • [8] Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
    Cortes, J.
    Kim, D-W
    Raffoux, E.
    Martinelli, G.
    Ritchie, E.
    Roy, L.
    Coutre, S.
    Corm, S.
    Hamerschlak, N.
    Tang, J-L
    Hochhaus, A.
    Khoury, H. J.
    Bruemmendorf, T. H.
    Michallet, M.
    Rege-Cambrin, G.
    Gambacorti-Passerini, C.
    Radich, J. P.
    Ernst, T.
    Zhu, C.
    Van Tornout, J. M. A.
    Talpaz, M.
    LEUKEMIA, 2008, 22 (12) : 2176 - 2183
  • [9] Dasatinib is a safe therapy for imatinib-resistant patients with chronic-phase CML
    Nature Clinical Practice Oncology, 2007, 4 (9): : 503 - 503
  • [10] Dasatinib is active in imatinib-resistant and imatinib-intolerant patients with CML
    Nature Clinical Practice Oncology, 2007, 4 (6): : 328 - 328
12345